

20
CLAIMS

1. A pharmaceutical composition comprising a pharmaceutically effective combination of
 - (i) a first compound selected from the group consisting of muscarinic receptor antagonists, 5 α -reductase inhibitors, and α -adrenergic receptor antagonists, and precursors and pharmaceutically acceptable salts thereof, and
 - (ii) a second compound selected from the group consisting of 5-HT_{1a} receptor agonists and antagonists, and precursors and pharmaceutically acceptable salts thereof,
- 10 and optionally a pharmaceutically acceptable carrier or diluent therefor.
2. A pharmaceutical composition according to claim 1, wherein said first compound is a muscarinic receptor antagonist, or a precursor or a pharmaceutically acceptable salt thereof.
3. A composition according to claim 2, wherein said muscarinic receptor antagonist is a substituted 3,3-diphenylpropylamine.
4. A composition according to claim 3, wherein said substituted 3,3-diphenylpropylamine is selected from the group consisting of tolterodine and hydroxytolterodine.
5. A composition according to claim 4, wherein said substituted 3,3-diphenylpropylamine is tolterodine.

6. A composition according to claim 5, wherein said first compound is tolterodine L-tartrate.
7. A composition according to claim 2, wherein said muscarinic receptor antagonist is selected from oxybutynin and active derivatives thereof, such as N-desethyloxybutynin.
8. A composition according to claim 7, wherein said muscarinic receptor antagonist is oxybutynin.
9. A composition according to claim 2, wherein said muscarinic receptor antagonist is selected from darifenacin and active derivatives thereof, such as its 3'-hydroxyl metabolite.
10. A composition according to claim 9, wherein said muscarinic receptor antagonist is darifenacin.
11. A composition according to any one of claims 1-10, wherein said first compound is present in an amount of from about 0.1 mg to about 100 mg.
12. A composition according to any one of claims 1-11, wherein said second compound is a neutral 5-HT_{1a} receptor antagonist.
13. A composition according to any one of claims 1-12, wherein said second compound is present in an amount of from about 0.1 mg to about 1 g.

14. A composition according to any one of claims 1-13, wherein said first compound and said second compound are maintained in the same delivery vehicle.

15. A composition according to any one of claims 1-13, wherein said first compound and said second compound are maintained in different delivery vehicles.

16. A composition according to any one of claims 1-15, which is for treating urinary disorder in a mammal, including man.

17. A composition according to claim 16, wherein said disorder is lower urinary tract symptoms.

18. A composition according to claim 16, wherein said disorder is unstable or overactive urinary bladder.

19. A composition according to claim 16, wherein said disorder is bladder outflow obstruction.

20. A composition according to claim 16, wherein said disorder is urinary incontinence.

21. A composition according to claim 20, wherein said disorder is stress incontinence.

22. A composition according to claim 16, wherein said disorder is interstitial cystitis.
23. A composition according to any one of claims 16-22, which is for treating depression in said mammal, which depression is concomitant with said urinary disorder.
24. Use of a pharmaceutical composition according to any one of claims 1-15 for the manufacture of a medicament for therapeutical treatment of urinary disorder in a mammal, including man.
25. Use of a pharmaceutical composition according to claim 24, wherein said disorder is lower urinary tract symptoms.
26. Use of a pharmaceutical composition according to claim 24, wherein said disorder is unstable or overactive urinary bladder.
27. Use of a pharmaceutical composition according to claim 24, wherein said disorder is bladder outflow obstruction.
28. Use of a pharmaceutical composition according to claim 24, wherein said disorder is urinary incontinence.
29. Use of a pharmaceutical composition according to claim 28, wherein said disorder is stress incontinence.

30. Use of a pharmaceutical composition according to claim 24, wherein said disorder is interstitial cystitis.

31. Use of a pharmaceutical composition according to any one of claims 24-30, wherein the medicament is for treatment of depression in said mammal, which depression is concomitant with said urinary disorder.

32. A method of therapeutical treatment of urinary disorder in a mammal, including man, comprising
administering to said mammal, including man, in need of such treatment, a therapeutically effective amount of a composition according to any one of claims 1-15.

33. A method of therapeutical treatment according to claim 32, wherein said disorder is lower urinary tract symptoms.

34. A method of therapeutical treatment according to claim 32, wherein said disorder is unstable or overactive urinary bladder.

35. A method of therapeutical treatment according to claim 32, wherein said disorder is bladder outflow obstruction.

36. A method of therapeutical treatment according to claim 32, wherein said disorder is urinary incontinence.

37. A method of therapeutical treatment according to claim 36, wherein said disorder is stress incontinence.

38. A method of therapeutical treatment according to claim 32, wherein said disorder is interstitial cystitis.

39. A method of therapeutical treatment according to any one of claims 32-38, which is also for treatment of depression in said mammal, which depression is concomitant with said urinary disorder.

40. A method of therapeutical treatment according to any one of claims 32-39, wherein said composition is administered rectally, intravaginally, topically, orally, sublingually, intranasally, transdermally or parenterally.

41. A method of therapeutical treatment according to any one of claims 32-40, wherein said first compound and said second compound of said composition are simultaneously administered.

42. A method of therapeutical treatment according to any one of claims 32-40, wherein said first compound and said second compound of said composition are concomitantly administered.

43. A pharmaceutical kit for therapeutical treatment of urinary disorder in a mammal, including man, comprising
- (i) a first container comprising a first compound according to any one of claims 1-10,
 - (ii) a second container comprising a second compound according to claim 1 or 12, and
- 5 optionally
- (iii) instructions for use of the kit.